Navigation Links
ChromaDex Announces 2008 Year End Financial Results
Date:4/3/2009

IRVINE, Calif., April 3 /PRNewswire-FirstCall/ -- ChromaDex Corporation, (OTC Bulletin Board: CDXC) a leader in phytochemical reference standards and contract research, today announced financial results for the 2008 Fiscal Year. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (U.S. GAAP), ChromaDex announced a net loss attributable to common stockholders of $0.07 per share for the twelve months ended January 3, 2009.

As of January 3, 2009, cash, cash equivalents, and marketable securities totaled $1 million.

"The FDA started implementing Good Manufacturing Practices for dietary supplements in June 2008," said Frank Jaksch, CEO and co-founder of ChromaDex. "There is a rapidly growing awareness both at the consumer and government regulatory level of the need for reference standards, analytical methods and other quality assurance methods to insure that products on the shelf not only contain what is claimed on the label, but are also safe and effective. We are confident that the increased awareness and demand for products that are healthy, natural, organic or green, will continue to provide an opportunity for ChromaDex. Additionally, we will continue to invest in products, services and intellectual property that will enable us to remain the reference standards market leader for the dietary supplement, food, beverage, personal care, and sport nutrition markets."

Additional Financial Results & Notes

On a reported basis, ChromaDex recorded revenue during 2008 of $4,506,301 as compared to $4,754,073 for the same period in 2007. The net loss attributable to common stockholders for the twelve months ended January 3, 2009, was $2,104,476 as compared to a net loss of $189,875 for the same period in 2007. The company notes that as a result of its closing of the reverse merger acquisition of Cody Resources, Inc. on June 20, 2008, investors are cautioned that the company's historical performance is not directly comparable.

About ChromaDex

ChromaDex is a leader in the development of Phytochemical and Botanical Reference Standards and the creation of associated intellectual property. ChromaDex is committed to sustainable "Green chemistry" and provides the dietary supplement, food, beverage, nutraceutical and cosmetic industries with the analytical tools and services to meet product regulatory, quality, efficacy and safety standards.

Forward-Looking Statements

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to: the ability to market, produce and sell the referenced ingredients; risks relating to product and customer demand, market acceptance of our products; the effect of economic conditions both nationally and internationally; the ability to protect our intellectual property rights; the impact of any litigation or infringement actions brought against us; competition from other providers and products; risks in product development; our ability to raise capital to fund continuing operations; the ability to complete transactions; and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

ChromaDex Corporation

10005 Muirlands Blvd, Suite G

Irvine, CA 92618

Phone 949-419-0288

Fax 949-419-0294

Email info@chromadex.com

www.chromadex.com

    ChromaDex Corporation and Subsidiaries

    Consolidated Statements of Operations
    Years Ended January 3, 2009 and December 29, 2007

                                                    2008        2007

    Sales                                        $4,506,301  $4,754,073

    Cost of goods sold                            3,274,800   3,122,461

     Gross profit                                 1,231,501   1,631,612

    Operating expenses:
     Selling                                        720,519     387,816
     General and administrative                   2,579,015   1,421,516
                                                  3,299,534   1,809,332

     Operating loss                              (2,068,033)   (177,720)

    Nonoperating (income) expenses:
     Interest expense                                70,079      31,815
     Interest and other income                      (33,636)    (19,660)
                                                     36,443      12,155

     Net loss                                   $(2,104,476)  $(189,875)


    Basic and Diluted loss per common share          $(0.07)     $(0.01)


    Basic and Diluted average common shares
     outstanding                                 28,312,934  26,514,481



'/>"/>
SOURCE ChromaDex Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ChromaDex Announces Second Quarter 2008 Financial Results
2. ChromaDex, Inc. Announces Completion of Reverse Merger With Cody Resources, Inc.
3. China Agri-Business Announces 2008 Operating Results
4. Verenium Announces Organizational Changes
5. ThermoGenesis Announces Abstracts to Be Presented at Upcoming Stem Cell Therapy Conference
6. Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis
7. Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis
8. Nuevolution Announces Progress in Its Collaboration With Merck & Co. Inc.
9. China Biologic Products Announces Strong 2008 Results
10. Senetek PLC Announces New Investor Communication Hotline
11. NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle ... people with peritoneal or pleural mesothelioma. Their findings are the subject of a new ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... to announce the launch of their brand, UP4™ Probiotics, into Target stores nationwide. ... years, is proud to add Target to its list of well-respected retailers. This ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
Breaking Biology Technology:
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
(Date:6/1/2016)... Favorable Government Initiatives Coupled With ... Identification to Boost Global Biometrics System Market Through 2021  ... report, " Global Biometrics Market By Type, By ... 2011 - 2021", the global biometrics market is projected ... of growing security concerns across various end use sectors ...
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
Breaking Biology News(10 mins):